NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
+8.92%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$284M
AUM Growth
+$284M
(+25%)
Cap. Flow
+$48.9M
Cap. Flow
% of AUM
17.24%
Top 10 Holdings %
Top 10 Hldgs %
63.96%
Holding
56
New
16
Increased
10
Reduced
3
Closed
18
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
$34M |
| 2 |
Viatris
VTRS
|
$19.9M |
| 3 |
Merck
MRK
|
$19.5M |
| 4 |
ABLX
Ablynx NV American Depositary Shares
ABLX
|
$15.9M |
| 5 |
SHPG
Shire pic
SHPG
|
$14.3M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$20.3M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$15.2M |
| 3 |
GSK
GSK
|
$14.5M |
| 4 |
Aclaris Therapeutics
ACRS
|
$10.7M |
| 5 |
AKAO
Achaogen, Inc.
AKAO
|
$9.22M |
Sector Composition
| 1 | Healthcare | 91.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $34M | 6.27% | +207,871 | New | +$34M |
|
|
SHPG
2
DELISTED
Shire pic
SHPG
| $25.1M | 4.63% | 161,949 +92,301 | +133% | +$14.3M |
|
|
3
Viatris
VTRS
$12.3B
| $19.9M | 3.67% | +470,296 | New | +$19.9M |
|
|
4
Merck
MRK
$210B
| $19.5M | 3.59% | +346,293 | New | +$19.5M |
|
|
ABLX
5
DELISTED
Ablynx NV American Depositary Shares
ABLX
| $15.9M | 2.94% | +637,884 | New | +$15.9M |
|
6
Insmed
INSM
$28.8B
| $15.6M | 2.87% | 498,921 +354,921 | +246% | +$11.1M |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $14.6M | 2.7% | 163,997 +44,336 | +37% | +$3.95M |
|
|
DOVA
8
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $13M | 2.41% | 453,032 +14,913 | +3% | +$429K |
|
|
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $12.3M | 2.26% | 311,516 +41,441 | +15% | +$1.63M |
|
10
Sangamo Therapeutics
SGMO
$157M
| $11.6M | 2.14% | 708,544 -72,456 | -9% | -$1.19M |
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $11M | 2.02% | 86,293 +6,521 | +8% | +$829K |
|
12
FibroGen
FGEN
$47.8M
| $9.52M | 1.76% | 200,841 -16,488 | -8% | -$782K |
|
|
SAGE
13
DELISTED
Sage Therapeutics
SAGE
| $9.2M | 1.7% | +55,834 | New | +$9.2M |
|
|
SCMP
14
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $9.16M | 1.69% | +510,486 | New | +$9.16M |
|
|
CBIO
15
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $8.07M | 1.49% | 480,442 +159,156 | +50% | +$2.67M |
|
|
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $7.55M | 1.39% | 925,327 +325,327 | +54% | +$2.65M |
|
17
Kura Oncology
KURA
$686M
| $6.82M | 1.26% | 445,550 +187,034 | +72% | +$2.86M |
|
|
IMMU
18
DELISTED
Immunomedics Inc
IMMU
| $6.54M | 1.21% | 404,528 -387,578 | -49% | -$6.26M |
|
19
Atara Biotherapeutics
ATRA
$84.6M
| $5.19M | 0.96% | +286,647 | New | +$5.19M |
|
|
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
| $4.94M | 0.91% | 536,568 +521,568 | +3,477% | +$4.8M |
|
21
Gyre Therapeutics
GYRE
$703M
| $4.24M | 0.78% | +311,175 | New | +$4.24M |
|
|
AVDL
22
Avadel Pharmaceuticals
AVDL
$1.43B
| $4.15M | 0.76% | +505,921 | New | +$4.15M |
|
23
CytomX Therapeutics
CTMX
$336M
| $3.8M | 0.7% | +179,870 | New | +$3.8M |
|
|
OTIC
24
DELISTED
Otonomy, Inc.
OTIC
| $3.35M | 0.62% | +602,748 | New | +$3.35M |
|
25
TherapeuticsMD
TXMD
$12.8M
| $3.19M | 0.59% | +528,351 | New | +$3.19M |
|